{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:03Z","timestamp":1792508583527,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40273-018-0740-4","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T04:41:12Z","timestamp":1544676072000},"page":"975-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma"],"prefix":"10.1007","volume":"37","author":[{"given":"Frederick W.","family":"Thielen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasuh C.","family":"B\u00fcy\u00fckkaramikli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Riemsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Fayter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Huertas Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Misso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Worthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Corro Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"740_CR1","unstructured":"National Institute for Health and Care Excellence. NICE technology appraisal guidance [Internet]. London: NICE, 2017. \n                    https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\n                    \n                  . Accessed Jul 2017."},{"key":"740_CR2","unstructured":"National Institute for Health and Care Excellence. Obinutuzumab for untreated advanced follicular lymphoma [Internet]. London: NICE, 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/ta513\n                    \n                  . Accessed Apr 2018."},{"issue":"9844","key":"740_CR3","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848\u201357.","journal-title":"Lancet"},{"issue":"5","key":"740_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.mpmed.2017.02.008","volume":"45","author":"S Ninkovic","year":"2017","unstructured":"Ninkovic S, Lambert J. Non-Hodgkin lymphoma. Medicine. 2017;45(5):297\u2013304.","journal-title":"Medicine"},{"issue":"12","key":"740_CR5","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/ajh.24200","volume":"90","author":"A Freedman","year":"2015","unstructured":"Freedman A. Follicular lymphoma: 2015 update on diagnosis and management. Am J Hematol. 2015;90(12):1171\u20138.","journal-title":"Am J Hematol"},{"key":"740_CR6","unstructured":"Haematological Malignancy Research Network (HMRN). Incidence: Follicular lymphoma [Internet]. York: Haematological Malignancy Research Network (HMRN) n.d. \n                    https:\/\/www.hmrn.org\/statistics\/incidence\n                    \n                  . Accessed 19 Jun 17."},{"issue":"5","key":"740_CR7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365.","journal-title":"Blood"},{"issue":"27","key":"740_CR8","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555\u201362.","journal-title":"J Clin Oncol"},{"issue":"5","key":"740_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3109\/10428194.2014.953144","volume":"56","author":"LJ Nastoupil","year":"2015","unstructured":"Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, et al. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma. 2015;56(5):1295\u2013302.","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"740_CR10","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516\u201322.","journal-title":"J Clin Oncol"},{"key":"740_CR11","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Gazyravo [sic]. London: EMA, 2014. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002799\/WC500167332.pdf\n                    \n                  . Apr 2018."},{"key":"740_CR12","unstructured":"European Medicines Agency. CHMP post-authorisation summary of positive opinion for Gazyvaro. London: EMA, 2016. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/002799\/WC500205392.pdf\n                    \n                  . Accessed Apr 2018."},{"key":"740_CR13","unstructured":"European Medicines Agency. CHMP post-authorisation summary of positive opinion for Gazyvaro (II-16). London: EMA, 2017. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/002799\/WC500231836.pdf\n                    \n                  . Accessed Apr 2018."},{"key":"740_CR14","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331\u201344.","journal-title":"N Engl J Med"},{"issue":"9759","key":"740_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42\u201351.","journal-title":"Lancet"},{"key":"740_CR16","doi-asserted-by":"crossref","unstructured":"Salles GA, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Abstract presented at the 55th Annual Meeting of the American Society of Hematology (ASH); 7\u201310 Dec 2013; New Orleans: US. Blood 2013;122(21) (no pagination).","DOI":"10.1182\/blood.V122.21.509.509"},{"key":"740_CR17","unstructured":"Haematological Malignancy Research Network. Patient\u2019s age and treatment for haematological malignancy: a report from the Haematological Malignancy Research Network (HMRN) [online PDF]. York: HMRN, 2014, p 39. \n                    https:\/\/www.hmrn.org\/Download.aspx?target=document&id=41\n                    \n                  . Accessed 20 Jun 17."},{"issue":"11","key":"740_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesquieres H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096\u2013101.","journal-title":"Am J Hematol"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"A294","DOI":"10.1016\/S1098-3015(10)63491-2","volume":"9","author":"D Wild","year":"2006","unstructured":"Wild D, Walker M, Pettengell R, Lewis G. Utility elicitation in patients with follicular lymphoma (PCN62). Value Health. 2006;9:A294.","journal-title":"Value Health"},{"key":"740_CR20","unstructured":"Joint Formulary Committee. British National Formulary [Internet]. London: BMJ Group and Pharmaceutical Press, 2017. \n                    https:\/\/www.medicinescomplete.com\/mc\/bnf\/current\/\n                    \n                  . Accessed Apr 2017."},{"key":"740_CR21","unstructured":"Department of Health. Drugs and pharmaceutical electronic market information (eMit) [Internet]. London: Department of Health, 2016. \n                    https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit\n                    \n                  . Accessed Mar 2017."},{"key":"740_CR22","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 [Internet]. London: NICE, 2013, p 93. \n                    https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword\n                    \n                  . Accessed 14 Jul 2017."},{"key":"740_CR23","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal. Obinutuzumab for untreated advanced follicular lymphoma: Final scope (Appendix B) [Internet]. London: NICE, March 2017, p 4. \n                    https:\/\/www.nice.org.uk\/guidance\/gid-ta10137\/documents\/final-scope\n                    \n                  . Accessed 9 Mar 17."},{"issue":"12","key":"740_CR24","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40273-017-0528-y","volume":"35","author":"NC B\u00fcy\u00fckkaramikli","year":"2017","unstructured":"B\u00fcy\u00fckkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, et al. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an Evidence Review Group perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 2017;35(12):1211\u201321.","journal-title":"PharmacoEconomics"},{"issue":"2","key":"740_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40273-017-0581-6","volume":"36","author":"NC B\u00fcy\u00fckkaramikli","year":"2018","unstructured":"B\u00fcy\u00fckkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, et al. Pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib: an Evidence Review Group perspective of an NICE Single Technology Appraisal. PharmacoEconomics. 2018;36(2):145\u201359.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"740_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743\u201354.","journal-title":"Med Decis Making"},{"issue":"26","key":"740_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20260","volume":"20","author":"E Kaltenthaler","year":"2016","unstructured":"Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, et al. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis. Health Technol Assess. 2016;20(26):1\u201348.","journal-title":"Health Technol Assess"},{"key":"740_CR28","doi-asserted-by":"crossref","unstructured":"B\u00fcy\u00fckkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, et al. Ribociclib with an aromatase inhibitor for previously untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer: an Evidence Review Group perspective of a NICE Single Technology Appraisal. PharmacoEconomics 2018.","DOI":"10.1007\/s40273-018-0708-4"},{"key":"740_CR29","unstructured":"Roche Products Limited. Annex I Summary of product characteristics. EMA document library: Roche Products Limited. 2018. Accessed 16 Apr 18."},{"key":"740_CR30","unstructured":"National Institute for Health and Care Excellence. Prescribed Services CQUIN Scheme: GE3 Hospital Medicines Optimisation [Internet]. London: NICE, 2018. \n                    https:\/\/www.england.nhs.uk\/publication\/ge3-hospital-medicines-optimisation\/\n                    \n                  . Accessed Jul 2018."},{"issue":"11","key":"740_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2165\/11536970-000000000-00000","volume":"28","author":"P O\u2019Neill","year":"2010","unstructured":"O\u2019Neill P, Devlin NJ. An analysis of NICE\u2019s \u2018restricted\u2019 (or \u2018optimized\u2019) decisions. PharmacoEconomics. 2010;28(11):987\u201393.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"740_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40258-018-0393-7","volume":"16","author":"R Dickson","year":"2018","unstructured":"Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, et al. EMA and NICE Appraisal Processes for cancer drugs: current status and uncertainties. Appl Health Econ Health Policy. 2018;16(4):429\u201332.","journal-title":"Appl Health Econ Health Policy"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0740-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0740-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0740-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:21:48Z","timestamp":1576196508000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0740-4"}},"subtitle":["An Evidence Review Group Evaluation of the NICE Single Technology Appraisal"],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0740-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"13 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Program (project number 16\/112\/02 STA) [see the HTA program website for further information\u2014]. This summary of the ERG report was compiled after the AC\u2019s review. The views and opinions expressed are the authors\u2019 and do not necessarily reflect those of the HTA Programme, NICE, NIHR, NHS, or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"FWT, NCB, RR, DF, NA, C-YW, VHC, KM, GW, JK, and ICR have no conflicts of interest to declare that are relevant to the content of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}